Quotes 5-day view Delayed Nasdaq
02/26/2021
03/01/2021
03/02/2021
03/03/2021
03/04/2021
Date
85(c)
87.28(c)
84.14(c)
76.17(c)
70.65(c)
Last
1 067 471
404 216
601 323
467 148
846 493
Volume
+1.86% +2.68% -3.60% -9.47% -7.25% Change
Sales 2021
18,0 M - -
Net income 2021
-444 M - -
Net cash position 2021
1 610 M - -
P/E ratio 2021
-9,08x
Yield 2021
-
Sales 2022
109 M - -
Net income 2022
-373 M - -
Net cash position 2022
1 623 M - -
P/E ratio 2022
-11,2x
Yield 2022
-
Capitalization
4 125 M 4 125 M -
EV / Sales 2021
140x
EV / Sales 2022
23,0x
Nbr of Employees
298
Free-Float
87,5%
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's...
Notations Surperformance© of Sage Therapeutics, Inc.
Trading Rating : Investor Rating :
All news about SAGE THERAPEUTICS, INC.
News in other languages on SAGE THERAPEUTICS, INC.
Analyst Recommendations on SAGE THERAPEUTICS, INC.
Chart SAGE THERAPEUTICS, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends SAGE THERAPEUTICS, INC.
Short Term Mid-Term Long Term Trends Bearish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
21
Average target price
101,20 $
Last Close Price
70,65 $
Spread / Highest target
165%
Spread / Average Target
43,2%
Spread / Lowest Target
-0,92%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
